Decoy Therapeutics (NASDAQ:DCOY) Releases Earnings Results

Decoy Therapeutics (NASDAQ:DCOY) released its quarterly earnings results on Thursday. The company reported ($3.53) EPS for the quarter, FiscalAI reports. The company had revenue of $0.31 million for the quarter.

Decoy Therapeutics Price Performance

Decoy Therapeutics stock traded down $0.04 during mid-day trading on Thursday, reaching $1.05. 35,213 shares of the company were exchanged, compared to its average volume of 763,215. The company has a fifty day simple moving average of $1.85 and a 200-day simple moving average of $5.20. Decoy Therapeutics has a 12 month low of $0.90 and a 12 month high of $16.92. The firm has a market cap of $2.52 million, a PE ratio of -0.03 and a beta of 0.76.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Decoy Therapeutics in a research note on Wednesday, September 9th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $30.00.

About Decoy Therapeutics

Decoy Therapeutics is a biotechnology company developing messenger RNA (mRNA)-based medicines. Its technology is intended to direct the body’s cells to produce therapeutic proteins, with the goal of addressing diseases through targeted biological mechanisms. The company’s research activities focus on applying its mRNA platform to potential treatments in areas including infectious disease and oncology. Its pipeline remains centered on investigational programs, and the company’s products are subject to the development, testing and regulatory approval processes required for biotechnology therapies.